RCRita Coutinho

Rita Coutinho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rita Coutinho has a total of 128 co-authors. Here are the top co-authors by number of shared publications:

  • Maria Gomes da Silva

    Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal

    5 shared publications
  • Andrew Wilson

    Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

    4 shared publications
  • Maria Calaminici

    Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

    4 shared publications
  • Andrew Clear

    Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

    3 shared publications
  • Andrew Owen

    Authors' Affiliations: 1Department of Hemato-Oncology, Barts Cancer Institute, Queen Mary University of London; 2Department of Histopathology, Barts Health NHS Trust, Royal London Hospital, London, United Kingdom; Departments of 3Hematology, and 4Pathology, Portuguese Institute of Oncology, Lisbon, Portugal

    3 shared publications
  • Janet Matthews

    Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

    3 shared publications

Latest Publications

  • Open Access

    Evidence and Equity Gaps in Clinical Care of Chronic Lymphocytic Leukaemia in Portugal: A Real‐World, Multicentre, Cohort Study

    by Susana Esteves, Inês Coelho, José Carda, Sara Duarte, Inês Carvalhais, Daniela Alves, Rita Coutinho, Maria Gomes da Silva

    Objectives: Targeted therapies have markedly improved outcomes in chronic lymphocytic leukaemia (CLL), particularly among patients with TP53 alterations and unmutated IGHV. However, real‐world studies report persistent inequalities in access to optimal care. This is the first study aimed at identifying gaps between clinical practice and evidence‐based recommendations in Portuguese patients with CLL, focusing on treatment patterns, molecular testing, and clinical outcomes. Methods: A multicentre, retrospective, cohort included all consecutive CLL patients treated between 2018 and 2020 in five Portuguese hospitals. Demographic, clinical, and genetic data were collected, including therapies up to third‐line, toxicities, response, relapse/progression, and survival. Results: Among 298 patients, chemoimmunotherapy (FCR/BR) was most frequent (38%), followed by targeted agents (32%). TP53 /del(17p) testing occurred in 70% and IGHV in 42%, with significant inter‐centre variability. Older age (> 65 years) was independently associated with lower testing rates. Despite guidelines, targeted therapies were underused, particularly in high‐risk (77%) and early‐relapsing (43%) patients. Five‐year overall survival was 73% in first‐line and 55% in relapsed/refractory treatment subgroups. Conclusions: We identified delayed and inconsistent adoption of molecular testing and targeted therapies in Portugal, which likely contributed to the suboptimal survival observed. National guidelines adapted to local resources could harmonize CLL care and improve outcomes.

  • Open Access

    Clonally Related Chronic Myelomonocytic Leukemia and Erdheim-Chester Disease with KRAS Mutation: A Rare and Challenging Case

    by Tiago Monteiro-Brás, Inês Araújo, Maria Luís Amorim, Alexandra Azevedo, Luísa Regadas, Raquel Faria, Rita Coutinho

  • Open Access

    P012: Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience

    by Francesca Pierdomenico, Raquel Marques, Dulcelena Neves, João. Gaião. Santos, Christopher Saunders, Rita Pinho Peixeiro, Marta Henriques, Ana Tome, Daniela Alves, Margarida Badior, et al.

  • Open Access

    DIFFUSE LARGE B CELL AND HIGH‐GRADE LYMPHOMAS: THERAPEUTIC RESPONSE ‐ DESCRIPTIVE RETROSPECTIVE UNICENTRIC ANALYSIS

    by C. L Pedrosa, B Castro, R. P Peixeiro, L Regadas, R Coutinho, R Cabral, J Coutinho

  • Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma—an analysis of 386 Portuguese patients

    by Rita Coutinho, J. Lobato, S. Esteves, J. Cabeçadas, M. Gomes da Silva

    The identification of high-risk patients deserving alternative first-line treatments to R-CHOP is a research priority in diffuse large B cell lymphoma (DLBCL). Despite the increasing recognition of biological features underlying aggressive behavior, clinical scores remain the basis for prognostic evaluation and treatment stratification in DLBCL. We performed a retrospective analysis of patients with DLBCL uniformly treated with immunochemotherapy with the aim of assessing the discriminative power of the NCCN international prognostic index (IPI) and the GELTAMO-IPI scores in risk group stratification and compared them with the IPI. Additionally, we investigated if bulky disease, gender, beta-2 microglobulin (β2m), body mass index, and B-symptoms have independent prognostic impact. We confirmed the discriminative ability of the three prognostic scores in terms of progression-free survival and overall survival and found that the NCCN-IPI performs better in the identification of a high-risk population compared to the IPI and the GELTAMO scores. In an attempt to improve the prognostic power of the NCCN-IPI we analyzed additional clinical variables. Bulky disease and elevated β2m were found to be independent predictors of prognosis when controlling for the NCCN-IPI risk groups. However, they seem to bring no incremental power to the latter in the identification of poor outcome patients. We support the use of the NCCN-IPI for the clinical identification of high-risk patients in DLBCL. Future studies to unravel the biological heterogeneity within NCCN-IPI groups are needed to improve risk prediction and design targeted therapies for poor prognosis patients.


  • Open Access

    Life expectancy of young adults with follicular lymphoma

    by A. Conconi, C. Lobetti-Bodoni, S. Montoto, A. Lopez-Guillermo, R. Coutinho, J. Matthews, S. Franceschetti, F. Bertoni, A. Moccia, P. M. V. Rancoita, et al.

    This study was aimed at investigating the clinical features and outcomes of follicular lymphoma (FL) patients younger than 40 years, which have not been extensively investigated yet. One hundred and fifty-five patients younger than 40 years were retrospectively studied from a series of 1002 FL patients diagnosed in four different European Oncology Centres (Barcelona, Spain; Bellinzona, Switzerland; London, UK; Novara, Italy) from 1985 to 2010. Patients younger than 40 had a lower incidence of elevated LDH, high beta2-microglobulin, and a high-risk Follicular Lymphoma International Prognostic Index (FLIPI) score, whereas bone marrow involvement and bulky and disseminated lymphadenopathy were more frequent. At a median follow-up of 10 years, younger patients, in comparison with those older than 40, had significantly better overall (OS), cause-specific survival (CSS), and progression-free survival (PFS), with 10-year OS rate of 81% versus 51% (P < 0.0001), 10-year CSS rate of 82% versus 60% (P < 0.0001), and 10-year PFS of 39% versus 24% (P = 0.0098). However, there were no significant CSS and PFS differences in comparison with the patients aged 40–60. In multivariate analysis, having the lymphoma diagnosed in the last two decades and a favourable FLIPI score were associated with a significantly longer PFS and CSS in younger patients, whereas only FLIPI retained statistical significance for OS. In our series, FL patients younger than 40 have a median OS of 24 years and their outcome seems to be improving over time. However, they still have a significantly shorter life expectancy than that of an age-matched general healthy population.


  • Open Access

    Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP

    by R. Coutinho, A. J. Clear, E. Mazzola, A. Owen, P. Greaves, A. Wilson, J. Matthews, A. Lee, R. Alvarez, M. G. D. Silva, et al.

    Gene expression studies have identified the microenvironment as a prognostic player in diffuse large B-cell lymphoma. However, there is a lack of simple immune biomarkers that can be applied in the clinical setting and could be helpful in stratifying patients. Immunohistochemistry has been used for this purpose but the results are inconsistent. We decided to reinvestigate the immune microenvironment and its impact using immunohistochemistry, with two systems of image analysis, in a large set of patients with diffuse large B-cell lymphoma. Diagnostic tissue from 309 patients was arrayed onto tissue microarrays. Results from 161 chemoimmunotherapy-treated patients were used for outcome prediction. Positive cells, percentage stained area and numbers of pixels/area were quantified and results were compared with the purpose of inferring consistency between the two semi-automated systems. Measurement cutpoints were assessed using a recursive partitioning algorithm classifying results according to survival. Kaplan-Meier estimators and Fisher exact tests were evaluated to check for significant differences between measurement classes, and for dependence between pairs of measurements, respectively. Results were validated by multivariate analysis incorporating the International Prognostic Index. The concordance between the two systems of image analysis was surprisingly high, supporting their applicability for immunohistochemistry studies. Patients with a high density of CD3 and FoxP3 by both methods had a better outcome. Automated analysis should be the preferred method for immunohistochemistry studies. Following the use of two methods of semi-automated analysis we suggest that CD3 and FoxP3 play a role in predicting response to chemoimmunotherapy in diffuse large B-cell lymphoma.


  • Open Access

    Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2

    by Aine McCarthy, Jacek Marzec, Andrew Clear, Robert D. Petty, Rita Coutinho, Janet Matthews, Andrew Wilson, Sameena Iqbal, Maria Calaminici, John G. Gribben, et al.

    Overexpression of the anti-apoptotic protein BCL-2 is characteristic of human follicular lymphoma (FL) and some cases of diffuse large B cell lymphoma (DLBCL). We aimed to determine autophagy status in primary FL and DLBCL samples and the BCL-2+/BCL-2- lymphoma cell lines using both autophagy PCR array and tissue microarray (TMA). A greater number of autophagy machinery genes were up-regulated in the BCL-2+ Su-DHL4 cell line compared with BCL-2- Su-DHL8 cells, at both the basal level and in response to autophagic stress. The autophagy-related gene expression profiles were determined in purified and unpurified malignant human lymph node biopsies. Seven autophagy machinery genes were up-regulated in purified FL B-cells compared with reactive B-cells. Only 2 autophagy machinery genes were up-regulated in DLBCL B-cells. In unpurified tissue biopsies, 20 of 46 genes in FL and 2 of 5 genes in DLBCL with increased expression were autophagy machinery genes. Expression of autophagy substrates p62 and LC3 were determined by TMAs. FL samples showed significantly decreased levels of both p62 and LC3 compared with reactive and DLBCL, indicative of an increased autophagy activity in FL. In summary, these results demonstrate that FL showed increased basal autophagy activity, regardless of overexpression of BCL-2 in this disease.


  • HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era

    by Rita Coutinho, Alessia D. Pria, Shreyans Gandhi, Katharine Bailey, Paul Fields, Kate Cwynarski, Andrew Wilson, Panagiotis Papanastasopoulos, Melinda Tenant-Flowers, Andrew Webb, et al.

    Objective: To compare the outcome of patients diagnosed with HIV infection and diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP in the cART era with that of a HIV-negative control group. Methods: From 2003 to 2011, 305 patients (97 HIV-positive) were diagnosed with DLBCL and treated with R-CHOP. Clinical features were compared using chi-square or Fisher's exact test. Survival analysis was performed using the Kaplan–Meier method and log-rank test. Multivariate analysis was performed using the Cox regression proportional hazards model. Results: HIV-positive patients had more B symptoms and extranodal sites of disease at diagnosis, but the proportion of patients with high-intermediate/high-risk disease according to the international prognostic index (IPI) was similar between groups. Response rate was 73%, both for patients with and without HIV infection. After a median follow-up of 48 months, 30 patients relapsed after achieving a complete remission, including four HIV-positive patients. Ninety-six patients have died (19 HIV-positive), 73 of them due to DLBCL. Three patients (one HIV-positive) died due to treatment toxicity. Patients with HIV infection had a significantly longer disease-free survival (DFS) (5-year: 94 vs. 77%; P = 0.03) and overall survival (OS) (78 and 64% for HIV-positive and HIV-negative patients, respectively; P = 0.03). These results were confirmed on multivariate analysis when controlled for other potential prognostic confounders. Conclusion: HIV-positive patients diagnosed with DLBCL in the cART era have an excellent outcome when treated with standard immunochemotherapy. Therefore, the choice of chemotherapy in patients with lymphoma should not be influenced by HIV status.


  • Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies

    by Rita Coutinho, Andrew James Clear, Andrew Owen, Andrew Wilson, Janet Matthews, Abigail Lee, Rute Alvarez, Maria Gomes da Silva, José Cabeçadas, Maria Calaminici, et al.

    Purpose: The opportunity to improve therapeutic choices on the basis of molecular features of the tumor cells is on the horizon in diffuse large B-cell lymphoma (DLBCL). Agents such as bortezomib exhibit selective activity against the poor outcome activated B-cell type (ABC) DLBCL. In order for targeted therapies to succeed in this disease, robust strategies that segregate patients into molecular groups with high reliability are needed. Although molecular studies are considered gold standard, several immunohistochemistry (IHC) algorithms have been published that claim to be able to stratify patients according to their cell-of-origin and to be relevant for patient outcome. However, results are poorly reproducible by independent groups. Experimental Design: We investigated nine IHC algorithms for molecular classification in a dataset of DLBCL diagnostic biopsies, incorporating immunostaining for CD10, BCL6, BCL2, MUM1, FOXP1, GCET1, and LMO2. IHC profiles were assessed and agreed among three expert observers. A consensus matrix based on all scoring combinations and the number of subjects for each combination allowed us to assess reliability. The survival impact of individual markers and classifiers was evaluated using Kaplan–Meier curves and the log-rank test. Results: The concordance in patient's classification across the different algorithms was low. Only 4% of the tumors have been classified as germinal center B-cell type (GCB) and 21% as ABC/non-GCB by all methods. None of the algorithms provided prognostic information in the R-CHOP (rituximab plus cyclophosphamide–adriamycin–vincristine–prednisone)–treated cohort. Conclusion: Further work is required to standardize IHC algorithms for DLBCL cell-of-origin classification for these to be considered reliable alternatives to molecular-based methods to be used for clinical decisions. Clin Cancer Res; 19(24); 6686–95. ©2013 AACR.